Literature DB >> 8800148

Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis.

J R Izbicki1, B Passlick, S B Hosch, B Kubuschock, C Schneider, C Busch, W T Knoefel, O Thetter, K Pantel.   

Abstract

The impact of lymphatic micrometastases on prognosis of non-small-cell lung cancer has not been clearly established. We therefore prospectively assessed the frequency, mode of mediastinal spread, and prognostic significance of lymphatic micrometastases in lymph nodes of 93 patients with completely resected non-small-cell lung cancer staged as pT1 to pT4 pN0 and pN1 by conventional histopathologic techniques. Frozen tissue sections from 471 lymph nodes that were staged as free of metastases by routine histopathologic examination were screened for micrometastases by the alkaline phosphatase-antialkaline phosphatase immunostaining technique with the monoclonal antibody Ber-Ep-4. Twenty of 73 patients (27.4%) with disease staged as pN0 and nine of 20 patients (45.0%) with disease staged as pN1 had nodal micrometastases. Eight of 17 patients with upper lobe primary tumors and five of 12 patients with lower lobe primary tumors exhibited skip micrometastases. Mean relapse-free survival was significantly increased in patients with pN0 disease without micrometastases (41.1 vs 29 months, p = 0.0081). In patients with pN1 disease, mean relapse-free and cancer-related survivals were also significantly increased if no micrometastases were found (34.8 and 38.2 months vs 18 and 23.5 months, p = 0.0157 and p = 0.0094). Patients with disease staged as pN0 and pN1 with micrometastases revealed no difference in cancer-related survival compared with a control population of patients with disease staged as pN2. The mode of spread was erratic. The prognosis of patients after upstaging of pN0 and pN1 disease according to results of immunohistochemical staining correlated strongly with the prognosis of patients whose disease was staged at the higher stages by conventional histopathologic examination. These findings could represent a new indication for adjuvant therapy, supporting extensive lymph node sampling for staging purposes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800148     DOI: 10.1016/S0022-5223(96)70044-2

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

1.  Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer.

Authors:  Hitoshi Ishikawa; Yuko Nakayama; Yoshizumi Kitamoto; Tetsuo Nonaka; Hidemasa Kawamura; Katsuyuki Shirai; Hideyuki Sakurai; Kazushige Hayakawa; Hideo Niibe; Takashi Nakano
Journal:  Lung       Date:  2006-11-03       Impact factor: 2.584

2.  Detection of lymph node involvement by cytokeratin immunohistochemistry is an independent prognostic factor after curative resection of esophageal cancer.

Authors:  Goran Marjanovic; Markus Schricker; Axel Walch; Axel zur Hausen; Ulrich T Hopt; Andreas Imdahl; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2010-10-26       Impact factor: 3.452

3.  Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival.

Authors:  Chun-Dong Gu; Toshihiro Osaki; Tsunehiro Oyama; Masaaki Inoue; Mantaro Kodate; Kazuhito Dobashi; Takeshi Oka; Kosei Yasumoto
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

Review 4.  Sentinel nodes in lung cancer: review of our 10-year experience.

Authors:  Hiroaki Nomori; Mitsutomo Kohno; Yotaro Izumi; Takashi Ohtsuka; Keisuke Asakura; Takashi Nakayama
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

Review 5.  Surgical strategies in the therapy of non-small cell lung cancer.

Authors:  Feras Al-Shahrabani; Daniel Vallböhmer; Sebastian Angenendt; Wolfram T Knoefel
Journal:  World J Clin Oncol       Date:  2014-10-10

6.  Detection of occult tumor cells in regional lymph nodes is associated with poor survival in pN0 non-small cell lung cancer: a meta-analysis.

Authors:  Zhicheng He; Yang Xia; Shaowen Tang; Yijiang Chen; Liang Chen
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

7.  Incidence and clinical relevance of non-small cell lung cancer lymph node micro-metastasis detected by staging endobronchial ultrasound-guided transbronchial needle aspiration.

Authors:  Adam R Belanger; Johnathan Hollyfield; Gabriella Yacovone; Agathe S Ceppe; Jason A Akulian; A Cole Burks; M Patricia Rivera; Leslie G Dodd; Jason M Long; Benjamin E Haithcock; Chad V Pecot
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

8.  Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer.

Authors:  Jun Zhao; Jiagen Li; Ning Li; Shugeng Gao
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

9.  Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.

Authors:  J S Keum; G Kong; S C Yang; D H Shin; S S Park; J H Lee; J D Lee
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Authors:  Stephanie J Gros; Nina Kurschat; Astrid Drenckhan; Thorsten Dohrmann; Evelyn Forberich; Katharina Effenberger; Uta Reichelt; Robert M Hoffman; Klaus Pantel; Jussuf T Kaifi; Jakob R Izbicki
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.